Outcomes driven innovation
Outcomes driven innovation
Molecular Imaging
Intelligent innovation. Made possible.
Canon Medical’s PET-CT systems have been designed to facilitate the assessment of disease pathology at an early phase for a more tailored treatment approach.
Clinical and Operational PET opportunities
Prostate-Specific Membrane Antigen, PSMA, PET imaging
Over 200,0001 cases of Prostate Cancer per year are diagnosed in the US.
New PSMA-targeted PET tracers, indicated for use in patients with suspected prostate cancer metastasis or recurrence, have been approved by the FDA.
| PET | Injected Dose |
|---|---|
| Piflufolastat F-18 | 9.8mCi |
Download Cartesion Prime Flyer
1 cdc.gov
Clinical results may vary due to clinical setting, patient presentation and other factors.
Navigate to personalized care.
Cartesion Prime
Navigation is about looking at the paths laid out in front of you and choosing the one that gets you where you want to be. This means having options. Consistent with our Made for Life philosophy—solutions made to improve the lives of patients, clinicians and administrators—Canon Medical is proud to offer a new path to digital PET/CT that helps you navigate to your future.
Molecular imaging solutions with no compromise for every patient. Every time.
Celesteion™ PUREViSION Edition PET/CT
This versatile system combines high performance PET and CT imaging for all radiology, oncology, and radiation oncology needs.
